Janney Montgomery Scott LLC Trims Stock Position in Axon Enterprise, Inc $AXON

Posted by George Bondi on Aug 16th, 2026

Janney Montgomery Scott LLC cut its stake in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 9.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,575 shares of the biotechnology company’s stock after selling 1,925 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Axon Enterprise were worth $10,974,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of AXON. Edgewood Management LLC purchased a new position in shares of Axon Enterprise during the fourth quarter valued at about $846,516,000. Wellington Management Group LLP lifted its holdings in Axon Enterprise by 326.9% in the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock worth $874,463,000 after buying an additional 1,179,038 shares during the period. Norges Bank purchased a new stake in Axon Enterprise in the fourth quarter worth about $515,764,000. Styrax Capital LP bought a new stake in Axon Enterprise during the 1st quarter valued at approximately $84,938,000. Finally, Sands Capital Management LLC boosted its position in Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock valued at $914,047,000 after acquiring an additional 167,095 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

Positive Sentiment: Northland Securities raised several future earnings estimates. The firm lifted its FY2027 EPS forecast to $6.49 from $5.53 and increased estimates for Q1–Q4 2027, as well as Q3 2026. The revisions suggest stronger anticipated earnings from Axon’s connected-device, software, AI and public-safety technology businesses.
Positive Sentiment: Axon raised its 2026 revenue-growth outlook to 32%–34%. Management cited strong momentum in connected devices, international demand, counter-drone products and AI-enabled software, supported by approximately $15.1 billion in future contracted bookings. Axon Enterprise Is Up 17.8% After Raising 2026 Revenue Outlook
Neutral Sentiment: Recent quarterly results exceeded expectations. Second-quarter revenue increased 35.3% year over year to $904.4 million and topped consensus, while adjusted EPS also beat estimates. However, reported net income and diluted EPS declined, highlighting the trade-off between rapid expansion and near-term profitability. The 5 Most Interesting Analyst Questions From Axon’s Q2 Earnings Call
Negative Sentiment: Northland reduced its FY2026 EPS forecast to $3.12 from $3.26 and cut its Q4 2026 estimate to $1.29 from $1.55. These downgrades indicate some near-term earnings pressure even though longer-term forecasts improved.
Negative Sentiment: Insider selling added pressure. A report attributed a 6.5% decline to recent insider sales, which can raise concerns about valuation or management’s view of near-term upside. Axon Enterprise Trading Down Following Insider Selling
Negative Sentiment: Valuation and margins remain risks. With a very high earnings multiple and reported margin contraction, investors may be demanding clearer evidence that revenue growth will translate into sustained profit growth.

Axon Enterprise Trading Down 0.4%

NASDAQ:AXON opened at $612.83 on Friday. Axon Enterprise, Inc has a one year low of $339.01 and a one year high of $794.29. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The company’s 50-day simple moving average is $526.06 and its 200 day simple moving average is $474.40. The firm has a market capitalization of $49.79 billion, a P/E ratio of 254.29, a PEG ratio of 12.50 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 earnings per share for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a net margin of 6.19% and a return on equity of 2.84%. The business had revenue of $904.39 million for the quarter, compared to analysts’ expectations of $876.42 million. During the same quarter in the prior year, the company earned $2.12 earnings per share. The business’s revenue was up 35.3% compared to the same quarter last year. As a group, analysts forecast that Axon Enterprise, Inc will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on AXON shares. Citizens Jmp reissued a “market outperform” rating and issued a $700.00 target price on shares of Axon Enterprise in a research report on Thursday, June 25th. JPMorgan Chase & Co. raised their target price on Axon Enterprise from $750.00 to $755.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Piper Sandler lifted their price target on Axon Enterprise from $724.00 to $732.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, July 21st. Finally, UBS Group increased their price objective on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $730.92.

View Our Latest Stock Analysis on Axon Enterprise

Insider Buying and Selling

In related news, President Joshua Isner sold 13,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the completion of the transaction, the president owned 169,125 shares of the company’s stock, valued at $82,609,106.25. This trade represents a 7.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Elizabeth Reid Coughlin sold 1,554 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $485.00, for a total value of $753,690.00. Following the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at approximately $16,501,640. This trade represents a 4.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 68,989 shares of company stock worth $36,016,932 over the last three months. Corporate insiders own 4.20% of the company’s stock.

Axon Enterprise Profile

(Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.